Showing results (711-720 of 5,681) with videos related to

Sort By:
Pageof 569
The Oncologist|May 29, 2025
Colorectal cancer in pregnancy: case discussions and real-world data as well as literature review on current knowledgeSuzanne Poulgrain, Ted Gibbons, Cian O'Leary, et al.
The Oncologist|June 23, 2025
The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching studyWen Wang, Xintian Xu, Hongming Liu, et al.
The Oncologist|June 19, 2025
The Oncologist, 2025, Vol, XX, Issue XX Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancerChenjing Zhu, Zhen Gong, Ping Yin, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
The Oncologist|June 14, 2025
Medicare spending and use of subcutaneous biologic formulations with hyaluronidaseJohn Kim, Aaron S Kesselheim, Edward R Scheffer Cliff, et al.
The Oncologist|June 14, 2025
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancerBeibei Jiang, Yile Shang, Xiang Zhang, et al.
The Oncologist|October 10, 2025
The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019Shanshan Wang, Xiaojing Yang, Zhongrong Gao, et al.
The Oncologist|October 7, 2025
Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trialHaojie Zhou, Minzhi Lv, Wei Li, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
The Oncologist|October 7, 2025
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLCFabio Salomone, Giorgia Novero, Oriana Ciani, et al.
Pageof 569